Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1995 Feb;73(2):158–163. doi: 10.1136/hrt.73.2.158

Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest.

D Böcker 1, M Block 1, F Isbruch 1, C Fastenrath 1, M Castrucci 1, D Hammel 1, H H Scheld 1, M Borggrefe 1, G Breithardt 1
PMCID: PMC483783  PMID: 7696026

Abstract

BACKGROUND--The availability of implantable cardioverter-defibrillators (ICD) that are capable of antitachycardia pacing may lead to an increased use of ICDs in patients with haemodynamically tolerated ventricular tachycardia without a history of cardiac arrest. The frequency of potentially life-threatening fast ventricular tachycardias (cycle length < 250 ms) was investigated in patients who had a third generation ICD with endocardial leads implanted because they had haemodynamically tolerated ventricular tachycardia without a history of cardiac arrest. METHODS--Between January 1990 and October 1993, 50 patients (age (mean (SD)) 60 (11); ejection fraction 39 (16)%; 82% with coronary artery disease and 8% with dilated cardiomyopathy) with haemodynamically tolerated ventricular tachycardia (cycle length (mean (SD)) 348 (60) ms; range 250-500 ms) and without a history of cardiac arrest were treated with third generation ICDs that were capable of antitachycardia pacing. Fast ventricular tachycardia had been induced in 14 (28%) during baseline electrophysiological study. The benefit of ICD treatment was estimated as the difference between total mortality and the occurrence of fast ventricular tachycardia that would have been fatal if it had not been terminated. RESULTS--During follow up of 17 (12) months, 33 patients (66%) had a total of 3861 episodes of ventricular tachycardia. 91% of these episodes were terminated by antitachycardia pacing. 11 patients (22%) had episodes of potentially life-threatening fast ventricular tachycardia and 3 of these also had inducible fast ventricular tachycardia. One patient died suddenly 27 months after implantation. The difference between survival without fast ventricular tachycardia and total mortality was 9%, 12%, 27%, and 27% at 6, 12, 18, and 24 months, respectively. CONCLUSIONS--About a fifth of patients who had been given an ICD to treat haemodynamically tolerated ventricular tachycardia and who had no history of cardiac arrest experienced fast ventricular tachycardia during follow up requiring immediate cardioversion. Prospective studies are needed to investigate whether the prognosis of patients with a history of haemodynamically tolerated ventricular tachycardia without cardiac arrest is improved by ICD therapy.

Full text

PDF
158

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bardy G. H., Troutman C., Poole J. E., Kudenchuk P. J., Dolack G. L., Johnson G., Hofer B. Clinical experience with a tiered-therapy, multiprogrammable antiarrhythmia device. Circulation. 1992 May;85(5):1689–1698. doi: 10.1161/01.cir.85.5.1689. [DOI] [PubMed] [Google Scholar]
  2. Brugada P., Talajic M., Smeets J., Mulleneers R., Wellens H. J. The value of the clinical history to assess prognosis of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Eur Heart J. 1989 Aug;10(8):747–752. doi: 10.1093/oxfordjournals.eurheartj.a059559. [DOI] [PubMed] [Google Scholar]
  3. Böcker D., Block M., Isbruch F., Wietholt D., Hammel D., Borggrefe M., Breithardt G. Do patients with an implantable defibrillator live longer? J Am Coll Cardiol. 1993 Jun;21(7):1638–1644. doi: 10.1016/0735-1097(93)90380-j. [DOI] [PubMed] [Google Scholar]
  4. Böcker D., Block M., Isbruch F., Wietholt D., Hammel D., Scheld H. H., Borggrefe M., Breithardt G. Comparison of frequency of aggravation of ventricular tachyarrhythmias after implantation of automatic defibrillators using epicardial versus nonthoracotomy lead systems. Am J Cardiol. 1993 May 1;71(12):1064–1068. doi: 10.1016/0002-9149(93)90574-v. [DOI] [PubMed] [Google Scholar]
  5. Dreifus L. S., Fisch C., Griffin J. C., Gillette P. C., Mason J. W., Parsonnet V. Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Pacemaker Implantation). J Am Coll Cardiol. 1991 Jul;18(1):1–13. doi: 10.1016/s0735-1097(10)80209-8. [DOI] [PubMed] [Google Scholar]
  6. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992 Jul 23;327(4):227–233. doi: 10.1056/NEJM199207233270403. [DOI] [PubMed] [Google Scholar]
  7. Fisher J. D., Johnston D. R., Furman S., Mercando A. D., Kim S. G. Long-term efficacy of antitachycardia pacing for supraventricular and ventricular tachycardias. Am J Cardiol. 1987 Dec 1;60(16):1311–1316. doi: 10.1016/0002-9149(87)90613-8. [DOI] [PubMed] [Google Scholar]
  8. Fogoros R. N., Elson J. J., Bonnet C. A., Fiedler S. B., Burkholder J. A. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol. 1990 Aug;16(2):381–386. doi: 10.1016/0735-1097(90)90590-l. [DOI] [PubMed] [Google Scholar]
  9. Fromer M., Brachmann J., Block M., Siebels J., Hoffmann E., Almendral J., Ohm O. J., den Dulk K., Coumel P., Camm A. J. Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants. Circulation. 1992 Aug;86(2):363–374. doi: 10.1161/01.cir.86.2.363. [DOI] [PubMed] [Google Scholar]
  10. Grimm W., Flores B. F., Marchlinski F. E. Complications of implantable cardioverter defibrillator therapy: follow-up of 241 patients. Pacing Clin Electrophysiol. 1993 Jan;16(1 Pt 2):218–222. doi: 10.1111/j.1540-8159.1993.tb01565.x. [DOI] [PubMed] [Google Scholar]
  11. Grimm W., Flores B. F., Marchlinski F. E. Electrocardiographically documented unnecessary, spontaneous shocks in 241 patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 1992 Nov;15(11 Pt 1):1667–1673. doi: 10.1111/j.1540-8159.1992.tb02953.x. [DOI] [PubMed] [Google Scholar]
  12. Hook B. G., Callans D. J., Kleiman R. B., Flores B. T., Marchlinski F. E. Implantable cardioverter-defibrillator therapy in the absence of significant symptoms. Rhythm diagnosis and management aided by stored electrogram analysis. Circulation. 1993 Jun;87(6):1897–1906. doi: 10.1161/01.cir.87.6.1897. [DOI] [PubMed] [Google Scholar]
  13. Kim S. G., Fisher J. D., Choue C. W., Gross J., Roth J., Ferrick K. J., Brodman R., Furman S. Influence of left ventricular function on outcome of patients treated with implantable defibrillators. Circulation. 1992 Apr;85(4):1304–1310. doi: 10.1161/01.cir.85.4.1304. [DOI] [PubMed] [Google Scholar]
  14. Kim S. G., Fisher J. D., Furman S., Gross J., Zilo P., Roth J. A., Ferrick K. J., Brodman R. Exacerbation of ventricular arrhythmias during the postoperative period after implantation of an automatic defibrillator. J Am Coll Cardiol. 1991 Nov 1;18(5):1200–1206. doi: 10.1016/0735-1097(91)90536-i. [DOI] [PubMed] [Google Scholar]
  15. Lehmann M. H., Saksena S. Implantable cardioverter defibrillators in cardiovascular practice: report of the Policy Conference of the North American Society of Pacing and Electrophysiology. NASPE Policy Conference Committee. Pacing Clin Electrophysiol. 1991 Jun;14(6):969–979. doi: 10.1111/j.1540-8159.1991.tb04143.x. [DOI] [PubMed] [Google Scholar]
  16. Lehmann M. H., Steinman R. T., Schuger C. D., Jackson K. The automatic implantable cardioverter defibrillator as antiarrhythmic treatment modality of choice for survivors of cardiac arrest unrelated to acute myocardial infarction. Am J Cardiol. 1988 Oct 1;62(10 Pt 1):803–805. doi: 10.1016/0002-9149(88)91226-x. [DOI] [PubMed] [Google Scholar]
  17. Luceri R. M., Habal S. M., David I. B., Puchferran R. L., Muratore C., Rabinovich R. Changing trends in therapy delivery with a third generation noncommitted implantable defibrillator: results of a large single center clinical trial. Pacing Clin Electrophysiol. 1993 Jan;16(1 Pt 2):159–164. doi: 10.1111/j.1540-8159.1993.tb01554.x. [DOI] [PubMed] [Google Scholar]
  18. Mason J. W. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med. 1993 Aug 12;329(7):452–458. doi: 10.1056/NEJM199308123290702. [DOI] [PubMed] [Google Scholar]
  19. Mirowski M., Reid P. R., Mower M. M., Watkins L., Gott V. L., Schauble J. F., Langer A., Heilman M. S., Kolenik S. A., Fischell R. E. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980 Aug 7;303(6):322–324. doi: 10.1056/NEJM198008073030607. [DOI] [PubMed] [Google Scholar]
  20. Mosteller R. D., Lehmann M. H., Thomas A. C., Jackson K. Operative mortality with implantation of the automatic cardioverter-defibrillator. Am J Cardiol. 1991 Nov 15;68(13):1340–1345. doi: 10.1016/0002-9149(91)90242-d. [DOI] [PubMed] [Google Scholar]
  21. Reid P. R., Mirowski M., Mower M. M., Platia E. V., Griffith L. S., Watkins L., Jr, Bach S. M., Jr, Imran M., Thomas A. Clinical evaluation of the internal automatic cardioverter-defibrillator in survivors of sudden cardiac death. Am J Cardiol. 1983 Jun;51(10):1608–1613. doi: 10.1016/0002-9149(83)90195-9. [DOI] [PubMed] [Google Scholar]
  22. Saksena S. Defibrillation thresholds and perioperative mortality associated with endocardial and epicardial defibrillation lead systems. The PCD investigators and participating institutions. Pacing Clin Electrophysiol. 1993 Jan;16(1 Pt 2):202–207. doi: 10.1111/j.1540-8159.1993.tb01562.x. [DOI] [PubMed] [Google Scholar]
  23. Saksena S., Poczobutt-Johanos M., Castle L. W., Fogoros R. N., Alpert B. L., Kron J., Pacifico A., Griffin J., Ruskin J. N., Kehoe R. F. Long-term multicenter experience with a second-generation implantable pacemaker-defibrillator in patients with malignant ventricular tachyarrhythmias. The Guardian Multicenter Investigators Group. J Am Coll Cardiol. 1992 Mar 1;19(3):490–499. doi: 10.1016/s0735-1097(10)80260-8. [DOI] [PubMed] [Google Scholar]
  24. Sweeney M. O., Ruskin J. N. Mortality benefits and the implantable cardioverter-defibrillator. Circulation. 1994 Apr;89(4):1851–1858. doi: 10.1161/01.cir.89.4.1851. [DOI] [PubMed] [Google Scholar]
  25. Trappe H. J., Klein H., Fieguth H. G., Kielblock B., Wenzlaff P., Lichtlen P. R. Clinical efficacy and safety of the new cardioverter defibrillator systems. Pacing Clin Electrophysiol. 1993 Jan;16(1 Pt 2):153–158. doi: 10.1111/j.1540-8159.1993.tb01553.x. [DOI] [PubMed] [Google Scholar]
  26. Wietholt D., Block M., Isbruch F., Böcker D., Borggrefe M., Shenasa M., Breithardt G. Clinical experience with antitachycardia pacing and improved detection algorithms in a new implantable cardioverter-defibrillator. J Am Coll Cardiol. 1993 Mar 15;21(4):885–894. doi: 10.1016/0735-1097(93)90343-y. [DOI] [PubMed] [Google Scholar]
  27. Winkle R. A., Mead R. H., Ruder M. A., Gaudiani V. A., Smith N. A., Buch W. S., Schmidt P., Shipman T. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol. 1989 May;13(6):1353–1361. doi: 10.1016/0735-1097(89)90310-0. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES